Day: March 10, 2021

THE WOODLANDS, Texas, March 10, 2021 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months and full-year ended December 31, 2020 and provided an update on key milestones.“During 2020, we substantially strengthened our balance sheet by eliminating 95% of our debt and returned to our roots by focusing on the advancement of our research and development pipeline,” said Lonnel Coats, Lexicon’s president and chief executive officer.  “We took key steps to advance our pipeline by initiating two proof-of-concept Phase 2 studies of LX9211 in diabetic peripheral neuropathic pain and post-herpetic neuralgia.  We efficiently closed out the sotagliflozin Phase 3 clinical program and, based on positive data from two of those Phase 3 studies, SCORED and SOLOIST, we believe that sotagliflozin...

ORLANDO, Fla., March 10, 2021 (GLOBE NEWSWIRE) — Franchise Group, Inc. (NASDAQ: FRG) (“Franchise Group” or the “Company”) today announced the completion of its previously announced acquisition of Pet Supplies Plus (“PSP”), a leading omnichannel retail chain and franchisor of pet supplies and services.In conjunction with the closing of its acquisition of PSP, Franchise Group obtained $1.3 billion in new debt financing, which, together with cash on hand, funded the $700 million acquisition of PSP and refinanced the balance of the Company’s outstanding term loans and revolving loans.Brian Kahn, President & CEO of Franchise Group said, “We are excited to welcome PSP, its management team, employees and franchisees to Franchise Group. We expect that PSP’s unit economics, expansion pipeline and execution track record will bring significant...

Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $85.6 million for full-year 2020 representing 17% growth over 2019First patient treated in high dose cohort of Phase 1 clinical trial evaluating the safety and tolerability of FX201 in patients with osteoarthritis of the kneePhase 1b trial of FX301 in post-operative pain expected to start in H1 2021Conference call scheduled for today at 4:30 p.m. ETBURLINGTON, Mass., March 10, 2021 (GLOBE NEWSWIRE) — Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter and the full year ended December 31, 2020.“Despite the unprecedented challenges presented by the global pandemic, 2020 was marked by solid commercial performance and important progress across all areas of the business,”...

SANTA PAULA, Calif., March 10, 2021 (GLOBE NEWSWIRE) — Calavo Growers, Inc. (Nasdaq-GS: CVGW), a global avocado-industry leader and provider of value-added fresh food, today reported its financial results for the first quarter ended January 31, 2021.First Quarter HighlightsTotal revenue of $220.6 million, a 19% decrease year over year, reflecting 2% growth in avocado volume offset by lower avocado prices and lower revenue in the Renaissance Food Group (“RFG”) and Foods segments.Gross profit of $17.8 million, or 8.1% of revenue, compared to $15.8 million, or 5.8% of revenue, for the comparable period last year. The increase in gross profit margin percentage was attributable to improvements in the Fresh segment.Net income of $5.3 million, or $0.30 per diluted share, compared to net loss of $0.9 million, or ($0.05) per diluted share...

– Preparations for potential launch of first Endocrinology Rare Disease product candidate, TransCon hGH (lonapegsomatropin), continues on track –– Oncology pipeline advancing into clinical trials beginning with TransCon TLR7/8 Agonist –– Conference call today at 4:30 p.m. Eastern Time –COPENHAGEN, Denmark, March 10, 2021 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced financial results for the full year ended December 31, 2020.“2020 was a year to remember for Ascendis as our global workforce delivered on time or ahead of schedule on all of our corporate milestones, advancing Vision 3×3, the company’s strategic roadmap through 2025 to build a leading biopharma company...

– The Neos Therapeutics Board of Directors recommend stockholders vote “FOR” the transaction in advance of the virtual special meeting scheduled for March 18, 2021 at 10:00 a.m. Eastern Time –– Stockholders are encouraged to vote, no matter how many or how few shares they own –– Vote TODAY by telephone, online at www.proxyvote.com, or by mailing proxy card –– MacKenzie Partners, the Company’s proxy solicitor, is available to answer any questions and help stockholders vote their shares –DALLAS and FORT WORTH, Texas, March 10, 2021 (GLOBE NEWSWIRE) — Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that leading independent proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) has recommended Neos Therapeutics...

Net Asset Value of $15.14 per Share as of December 31, 2020Board of Directors Declares $0.25 Per Share DividendExited Palantir Technologies, Inc. Position for $119M Total Realized GainSAN FRANCISCO, March 10, 2021 (GLOBE NEWSWIRE) — SuRo Capital Corp. (“SuRo Capital”, the “Company”, “we”, “us”, and “our”) (Nasdaq: SSSS) today announced its financial results for the fourth quarter and fiscal year ended December 31, 2020. Net assets totaled approximately $301.6 million, or $15.14 per share, at December 31, 2020, inclusive of dividends totaling $0.47 per share declared during the fourth quarter, as compared to $12.46 per share at September 30, 2020 and $11.38 per share at December 31, 2019.“As of year-end 2020, SuRo Capital reported its highest dividend-adjusted net asset value per share since September 2015, driven by positive developments...

Radnor, PA, March 10, 2021 (GLOBE NEWSWIRE) — BM Technologies, Inc. (NYSE American: BMTX, BMTX.W), one of the largest digital banking platforms in the country, will release its fourth quarter and full year 2020 results after the market closes on March 16, 2021.The earnings release will be available on BM Technologies, Inc.’s (BMTX) investor relations website: https://ir.bmtxinc.com/overview/default.aspx.ContactsInvestor Relations:Bob RamseyChief Financial Officer, BM Technologies, Inc. (BMTX)484-926-7118rramsey@bankmobile.comMedia Inquiries:Kati WaldenburgVice President, Rubenstein Public Relations, Inc.212-805-3014kwaldenburg@rubensteinpr.com# # # About BM Technologies, Inc.BM Technologies, Inc. (NYSE American: BMTX, BMTX.W) is among the largest digital banking platforms in the U.S., providing access to checking and savings accounts,...